Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 162

1.

Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.

Garland SM, Joura EA, Ault KA, Bosch FX, Brown DR, Castellsagué X, Ferenczy A, Ferris DG, Giuliano AR, Hernandez-Avila M, Huh WK, Iversen OE, Kjaer SK, Kurman RJ, Luna J, Monsonego J, Muñoz N, Paavonen J, Pitisuttihum P, Ronnett BM, Steben M, Stoler MH, Wheeler CM, Wiley DJ, Perez G, Saah AJ, Luxembourg A, Li S, DiNubile MJ, Wagner M, Velicer C.

Obstet Gynecol. 2018 Aug;132(2):261-270. doi: 10.1097/AOG.0000000000002736.

PMID:
29995724
2.

Response to Donahue et al. 2017 in press article.

Ault KA, Riley LE.

Vaccine. 2018 Apr 19;36(17):2230. doi: 10.1016/j.vaccine.2017.12.031. Epub 2018 Jan 3. No abstract available.

PMID:
29306504
3.

Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by region.

Castellsagué X, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris DG, Joura EA, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Monsonego J, Muñoz N, Myers E, Paavonen J, Pitisuttihum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Papillomavirus Res. 2016 Dec;2:61-69. doi: 10.1016/j.pvr.2016.03.002. Epub 2016 Mar 14.

4.

Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16-26 years: a randomised, double-blind trial.

Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH, Ruiz-Sternberg AM, Stapleton JT, Wiley DJ, Ferenczy A, Kurman R, Ronnett BM, Stoler MH, Cuzick J, Garland SM, Kjaer SK, Bautista OM, Haupt R, Moeller E, Ritter M, Roberts CC, Shields C, Luxembourg A.

Lancet. 2017 Nov 11;390(10108):2143-2159. doi: 10.1016/S0140-6736(17)31821-4. Epub 2017 Sep 5.

PMID:
28886907
5.

Evaluation of two vaccine education interventions to improve pertussis vaccination among pregnant African American women: A randomized controlled trial.

Kriss JL, Frew PM, Cortes M, Malik FA, Chamberlain AT, Seib K, Flowers L, Ault KA, Howards PP, Orenstein WA, Omer SB.

Vaccine. 2017 Mar 13;35(11):1551-1558. doi: 10.1016/j.vaccine.2017.01.037. Epub 2017 Feb 16.

6.

Impact of a multi-component antenatal vaccine promotion package on improving knowledge, attitudes and beliefs about influenza and Tdap vaccination during pregnancy.

Chamberlain AT, Seib K, Ault KA, Rosenberg ES, Frew PM, Cortes M, Whitney EA, Berkelman RL, Orenstein WA, Omer SB.

Hum Vaccin Immunother. 2016 Aug 2;12(8):2017-2024. Epub 2016 Apr 15.

7.

Trends in reasons for non-receipt of influenza vaccination during pregnancy in Georgia, 2004-2011.

Chamberlain AT, Berkelman RL, Ault KA, Rosenberg ES, Orenstein WA, Omer SB.

Vaccine. 2016 Mar 18;34(13):1597-1603. doi: 10.1016/j.vaccine.2016.01.058. Epub 2016 Feb 6.

8.

Cervical Cancer Screening in the United States-Affiliated Pacific Islands: Options and Opportunities.

Waxman AG, Buenconsejo-Lum LE, Cremer M, Feldman S, Ault KA, Cain JM, Diaz ML; Expert Panel on Cervical Cancer Screening in the US Territories Pacific Island Jurisdictions.

J Low Genit Tract Dis. 2016 Jan;20(1):97-104. doi: 10.1097/LGT.0000000000000161.

9.

The Expanded Impact of Human Papillomavirus Vaccine.

Pahud BA, Ault KA.

Infect Dis Clin North Am. 2015 Dec;29(4):715-24. doi: 10.1016/j.idc.2015.07.007. Review.

PMID:
26610422
10.

Improving influenza and Tdap vaccination during pregnancy: A cluster-randomized trial of a multi-component antenatal vaccine promotion package in late influenza season.

Chamberlain AT, Seib K, Ault KA, Rosenberg ES, Frew PM, Cortés M, Whitney EA, Berkelman RL, Orenstein WA, Omer SB.

Vaccine. 2015 Jul 9;33(30):3571-9. doi: 10.1016/j.vaccine.2015.05.048. Epub 2015 Jun 1.

11.

Factors Associated with Intention to Receive Influenza and Tetanus, Diphtheria, and Acellular Pertussis (Tdap) Vaccines during Pregnancy: A Focus on Vaccine Hesitancy and Perceptions of Disease Severity and Vaccine Safety.

Chamberlain AT, Seib K, Ault KA, Orenstein WA, Frew PM, Malik F, Cortés M, Cota P, Whitney EA, Flowers LC, Berkelman RL, Omer SB.

PLoS Curr. 2015 Feb 25;7. pii: ecurrents.outbreaks.d37b61bceebae5a7a06d40a301cfa819. doi: 10.1371/currents.outbreaks.d37b61bceebae5a7a06d40a301cfa819.

12.

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH.

Gynecol Oncol. 2015 Feb;136(2):178-82. doi: 10.1016/j.ygyno.2014.12.022. Epub 2015 Jan 8.

PMID:
25579107
13.

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH.

J Low Genit Tract Dis. 2015 Apr;19(2):91-6. doi: 10.1097/LGT.0000000000000103.

PMID:
25574659
14.

Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance.

Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FA, Kinney WK, Massad LS, Mayeaux EJ, Saslow D, Schiffman M, Wentzensen N, Lawson HW, Einstein MH.

Obstet Gynecol. 2015 Feb;125(2):330-7. doi: 10.1097/AOG.0000000000000669.

PMID:
25569009
15.

Attribution of 12 high-risk human papillomavirus genotypes to infection and cervical disease.

Joura EA, Ault KA, Bosch FX, Brown D, Cuzick J, Ferris D, Garland SM, Giuliano AR, Hernandez-Avila M, Huh W, Iversen OE, Kjaer SK, Luna J, Miller D, Monsonego J, Munoz N, Myers E, Paavonen J, Pitisuttithum P, Steben M, Wheeler CM, Perez G, Saah A, Luxembourg A, Sings HL, Velicer C.

Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1997-2008. doi: 10.1158/1055-9965.EPI-14-0410.

16.

Women's health providers as vaccine providers in public health emergencies.

Van Otterloo J, Seib K, Ault KA, Omer SB.

J Reprod Med. 2014 Jul-Aug;59(7-8):401-8.

PMID:
25098031
17.

"Doctor, it hurts…".

Ault KA.

Obstet Gynecol. 2014 Feb;123(2 Pt 1):223-4. doi: 10.1097/AOG.0000000000000119. No abstract available.

PMID:
24402604
18.

Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments.

Sheffield JS, Munoz FM, Beigi RH, Rasmussen SA, Edwards KM, Read JS, Heine RP, Ault KA, Swamy GK, Jevaji I, Spong CY, Fortner KB, Patel SM, Nesin M.

Vaccine. 2013 Sep 13;31(40):4264-73. doi: 10.1016/j.vaccine.2013.07.031. Epub 2013 Jul 29.

PMID:
23906887
19.

Beyond likes and tweets: an in-depth look at the physician social media landscape.

Fogelson NS, Rubin ZA, Ault KA.

Clin Obstet Gynecol. 2013 Sep;56(3):495-508. doi: 10.1097/GRF.0b013e31829e7638.

PMID:
23835911
20.

Programmatic and research priorities for improving influenza immunization of pregnant women.

Ault KA, Heine RP, Riley LE.

Am J Obstet Gynecol. 2012 Sep;207(3 Suppl):S75-7. doi: 10.1016/j.ajog.2012.06.078. Epub 2012 Jul 9. Review.

PMID:
22920064
21.

Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.

Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM; FUTURE I and II Study Group.

BMJ. 2012 Mar 27;344:e1401. doi: 10.1136/bmj.e1401.

22.

Behavioral and sociodemographic risk factors for serological and DNA evidence of HPV6, 11, 16, 18 infections.

Wiley DJ, Masongsong EV, Lu S, Heather L S, Salem B, Giuliano AR, Ault KA, Haupt RM, Brown DR.

Cancer Epidemiol. 2012 Jun;36(3):e183-9. doi: 10.1016/j.canep.2011.12.007. Epub 2012 Jan 25.

PMID:
22277329
23.

Cervical cancer prevention: better tests, better tools, and more equitable outcomes.

Ault KA.

J Natl Cancer Inst. 2011 Sep 21;103(18):1352-3. doi: 10.1093/jnci/djr330. Epub 2011 Sep 6. No abstract available.

PMID:
21900118
24.

Advancing human papillomavirus research with a rhesus monkey model.

Ault KA, Brown DR.

J Natl Cancer Inst. 2011 May 4;103(9):703. doi: 10.1093/jnci/djr125. Epub 2011 Apr 11. No abstract available.

PMID:
21483022
25.

Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia.

Lehtinen M, Ault KA, Lyytikainen E, Dillner J, Garland SM, Ferris DG, Koutsky LA, Sings HL, Lu S, Haupt RM, Paavonen J; FUTURE I and II Study Group.

Sex Transm Infect. 2011 Aug;87(5):372-6. doi: 10.1136/sti.2010.044354. Epub 2011 Apr 6.

26.

Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine.

Ault KA, Joura EA, Kjaer SK, Iversen OE, Wheeler CM, Perez G, Brown DR, Koutsky LA, Garland SM, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Majewski S, Muñoz N, Sings HL, Harkins K, Rutkowski MA, Haupt RM, Garner EI; FUTURE I and II Study Group.

Int J Cancer. 2011 Mar 15;128(6):1344-53. doi: 10.1002/ijc.25723. Epub 2011 Jan 12.

27.

Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.

FUTURE I/II Study Group, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Maansson R, Lu S, Vuocolo S, Hesley TM, Barr E, Haupt R.

BMJ. 2010 Jul 20;341:c3493. doi: 10.1136/bmj.c3493.

28.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534. Epub 2010 Feb 5.

PMID:
20139221
29.

Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials.

Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, Saah A, Marino D, Ryan D, Radley D, Zhou H, Haupt RM, Garner EI; Quadrivalent Human Papillomavirus Vaccine Phase III Investigators.

Obstet Gynecol. 2009 Dec;114(6):1179-88. doi: 10.1097/AOG.0b013e3181c2ca21.

PMID:
19935017
30.

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection.

Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.

Hum Vaccin. 2009 Oct;5(10):696-704. Epub 2009 Oct 1.

PMID:
19855170
31.

Safety of influenza vaccination during pregnancy.

Tamma PD, Ault KA, del Rio C, Steinhoff MC, Halsey NA, Omer SB.

Am J Obstet Gynecol. 2009 Dec;201(6):547-52. doi: 10.1016/j.ajog.2009.09.034. Epub 2009 Oct 21. Review.

PMID:
19850275
32.

A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.

Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Maansson R, Lu S, Vuocolo S, Hesley TM, Saah A, Barr E, Haupt RM.

Cancer Prev Res (Phila). 2009 Oct;2(10):868-78. doi: 10.1158/1940-6207.CAPR-09-0031. Epub 2009 Sep 29.

33.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):926-35. doi: 10.1086/597307.

PMID:
19236279
34.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.

Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):936-44. doi: 10.1086/597309.

PMID:
19236277
35.

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.

Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch X, Dillner J, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Lu S, Vuocolo S, Hesley TM, Haupt RM, Barr E.

Vaccine. 2008 Dec 9;26(52):6844-51. doi: 10.1016/j.vaccine.2008.09.073. Epub 2008 Oct 16.

PMID:
18930097
36.

Human papillomavirus vaccines: an update for gynecologists.

Ault KA.

Clin Obstet Gynecol. 2008 Sep;51(3):527-32. doi: 10.1097/GRF.0b013e31818092df. Review.

PMID:
18677145
37.

New antibiotics and vaccines in obstetric practice. Foreword.

Ault KA.

Clin Obstet Gynecol. 2008 Sep;51(3):485. doi: 10.1097/GRF.0b013e3181844f52. No abstract available.

PMID:
18677140
38.

Human papillomavirus vaccines and the potential for cross-protection between related HPV types.

Ault KA.

Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S31-3. Review.

PMID:
18499916
39.

Long-term efficacy of human papillomavirus vaccination.

Ault KA.

Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S27-30. Review.

PMID:
17938016
40.

Regulation of surfactant protein D in the mouse female reproductive tract in vivo.

Oberley RE, Goss KL, Hoffmann DS, Ault KA, Neff TL, Ramsey KH, Snyder JM.

Mol Hum Reprod. 2007 Dec;13(12):863-8. Epub 2007 Oct 22.

PMID:
17954522
42.

Does rubella immunity predict measles immunity? A serosurvey of pregnant women.

Kennedy CM, Burns BA, Ault KA.

Infect Dis Obstet Gynecol. 2006;2006:13890.

43.

Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine.

Fraser C, Tomassini JE, Xi L, Golm G, Watson M, Giuliano AR, Barr E, Ault KA.

Vaccine. 2007 May 22;25(21):4324-33. Epub 2007 Mar 12.

PMID:
17445955
44.
45.

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18.

Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, Brown DR, Ferenczy A, Harper DM, Koutsky LA, Kurman RJ, Lehtinen M, Malm C, Olsson SE, Ronnett BM, Skjeldestad FE, Steinwall M, Stoler MH, Wheeler CM, Taddeo FJ, Yu J, Lupinacci L, Railkar R, Marchese R, Esser MT, Bryan J, Jansen KU, Sings HL, Tamms GM, Saah AJ, Barr E.

Vaccine. 2006 Jul 7;24(27-28):5571-83. Epub 2006 May 15.

PMID:
16753240
46.

Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review.

Ault KA.

Obstet Gynecol Surv. 2006 Jun;61(6 Suppl 1):S26-31. Review.

PMID:
16729901
47.

Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.

Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E.

Obstet Gynecol. 2006 Jan;107(1):18-27. Erratum in: Obstet Gynecol. 2006 Jun;107(6):1425.

PMID:
16394035
48.

Alcohol consumption and platelet activation and aggregation among women and men: the Framingham Offspring Study.

Mukamal KJ, Massaro JM, Ault KA, Mittleman MA, Sutherland PA, Lipinska I, Levy D, D'Agostino RB, Tofler GH.

Alcohol Clin Exp Res. 2005 Oct;29(10):1906-12.

PMID:
16269922
49.

Gonorrhea and chlamydia infection among women visiting family planning clinics: racial variation in prevalence and predictors.

Einwalter LA, Ritchie JM, Ault KA, Smith EM.

Perspect Sex Reprod Health. 2005 Sep;37(3):135-40.

PMID:
16150661
50.

A role for surfactant protein D in innate immunity of the human prostate.

Oberley RE, Goss KL, Dahmoush L, Ault KA, Crouch EC, Snyder JM.

Prostate. 2005 Nov 1;65(3):241-51.

PMID:
15948134

Supplemental Content

Support Center